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Abstract
Introduction: Large deletions of the NF1 gene and its flanking regions are frequently associated with a severe
clinical manifestation. Different types of gross NF1 deletion have been identified that are distinguishable both by
their size and the number of genes included within the deleted regions. Type-1 NF1 deletions encompass 1.4 Mb
and include 14 genes, whereas the much less common type-2 NF1 deletions span 1.2 Mb and contain 13 genes.
Genotype-phenotype correlations in patients with large NF1 deletions are likely to be influenced by the nature and
number of the genes deleted in addition to the NF1 gene. Whereas the clinical phenotype associated with type-1
NF1 deletions has been well documented, the detailed clinical characterization of patients with non-mosaic type-2
NF1 deletions has not so far been reported.
Case presentation: In the present report we characterized two Caucasian European patients with non-mosaic
(germline) type-2 NF1 deletions. Our first patient was a 13-year-old girl with dysmorphic facial features, mild
developmental delay, large hands and feet, hyperflexibility of the joints, macrocephaly and T2 hyperintensities in
the brain. A whole-body magnetic resonance imaging scan indicated two internal plexiform neurofibromas. Our
second patient was an 18-year-old man who exhibited dysmorphic facial features, developmental delay, learning
disability, large hands and feet, hyperflexibility of the joints, macrocephaly and a very high subcutaneous and
internal tumor load as measured volumetrically on whole-body magnetic resonance imaging scans. At the age of
18 years, he developed a malignant peripheral nerve sheath tumor and died from secondary complications. Both
our patients exhibited cardiovascular malformations.
Conclusions: Our two patients with non-mosaic type-2 NF1 deletions exhibited clinical features that have been
reported in individuals with germline type-1 NF1 deletions. Therefore, a severe disease manifestation is not
confined to only patients with type-1 NF1 deletions but may also occur in individuals with type-2 NF1 deletions.
Our findings support the concept of an NF1 microdeletion syndrome with severe clinical manifestation that is
caused by type-1 as well as type-2 NF1 deletions.
Introduction
Neurofibromatosis type I (NF1) is an autosomal-domi-
nant inherited disease with an estimated frequency of
1:3000 [1]. The classic hallmarks of NF1 include café-
au-lait spots, axillary and inguinal freckling, neurofibro-
mas and Lisch nodules. Approximately 95% of all
patients with NF1 harbor mutations within the NF1
gene, whereas 5% have large deletions that encompass
the NF1 gene and its flanking regions [2]. From a clini-
cal point of view, the molecular diagnosis of a large NF1
deletion is important because they are frequently asso-
ciated with severe clinical manifestations [3-6] including
an increased risk of malignant peripheral nerve sheath
tumors (MPNSTs) as compared with the general NF1
population [7]. MPNSTs and gliomas together represent
the most common causes of reduced life expectancy
among patients with NF1 [8]. * Correspondence: hildegard.kehrer-sawatzki@uni-ulm.de
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far been reported: the type-1 deletion, present in 70% to
80% of all patients with NF1 with large NF1 deletions, is
the most frequent [6,9]. The breakpoints of type-1 NF1
deletions are located within low-copy repeats, termed
NF1-REPa and NF1-REPc [10]. Type-1 deletions encom-
pass 1.4 Mb and lead to the loss of 14 genes (Figure 1).
By contrast, type-2 NF1 deletions span 1.2 Mb and
include only 13 genes since LRRC37B is not deleted
(Figure 1). The breakpoints of type-2 deletions are
located within SUZ12 and its pseudogene SUZ12P
[11-13]. With an estimated frequency of 9% to 20%,
type-2 deletions are less frequent than type-1 NF1 dele-
tions [6,9,12]. A third type of recurrent NF1 deletion
(type-3) has recently been reported which encompass
1.0 Mb and include nine genes (Figure 1) [6,14]. In
addition to these three types of recurrent NF1 deletion
mediated by non-allelic homologous recombination
(NAHR), an amorphous group of atypical NF1 deletions
has also been observed in a subset of patients. These
atypical NF1 deletions are characterized by non-recur-
rent breakpoints and they are highly heterogeneous in
terms of their size, breakpoint position and the number
of genes present within the deleted region [6,9].
It is widely assumed that genotype-phenotype correla-
tions in patients with large NF1 deletions are likely to
be influenced by both the number and type of deleted
genes. The comprehensive clinical characterization of 29
patients with NF1 with molecularly ascertained type-1
NF1 deletions identified several features that are fre-
quently associated with this type of deletion [5]. These
features include dysmorphic facial features, tall stature,
large hands and feet, scoliosis, developmental delay,
learning disabilities and a high burden of subcutaneous,
plexiform and spinal neurofibromas.
In contrast to the well documented clinical phenotype
associated with type-1 NF1 deletions, the detailed clini-
cal investigation of patients with non-mosaic type-2 NF1
deletion has not been published so far. Type-2 deletions
frequently arise during post-zygotic cell division and
consequently give rise to somatic mosaicism with nor-
mal cells alongside those cells harboring the deletion
[11-13]. At least 44% of all patients with NF1 with type-
2 NF1 deletions exhibit somatic mosaicism [9] but their
prevalence may well be under-estimated [12]. Studies of
genotype-phenotype correlations in patients with mosaic
type-2 NF1 deletions are inherently difficult to perform
because the number of normal cells lacking the deletion
in different tissues (and hence their impact on the clini-
cal phenotype) is difficult to assess. Somatic mosaicism
is very likely to exert a major influence on disease sever-
ity since patients with mosaic large NF1 deletions often
display a mild clinical phenotype [11-13]. Whereas
somatic mosaicism is an issue that needs to be
addressed in all cases of type-2 NF1 deletion, somatic
mosaicism is rare among patients with type-1 NF1 dele-
tions, occurring in only 2% to 4% of cases [9].
In order to assess the phenotype associated with type-
2 NF1 deletions, careful clinical examination of patients
with non-mosaic (germline) type-2 NF1 deletions is cri-
tically important. However, germline type-2 NF1 dele-
tions are rare, with an estimated frequency of < 6%
among patients with NF1 with gross NF1 gene deletions
[9]. In a previous study, we specifically sought type-2
NF1 deletions among patients with NF1 deletion in
order to explore the causative mutational mechanisms
underlying these deletions [13]. We succeeded in identi-
fying 18 patients with type-2 deletions, 16 of whom
exhibited somatic mosaicism with normal cells. The
remaining two patients with type-2 NF1 deletions in
SUZ12P
CRLF3
ATAD5 C17orf42
ADAP2 RNF135
NF1 OMG
EVI2B
EVI2A
RAB11FIP4 C17orf79 UTP6 SUZ12
Type-1 NF1 deletion (1.4 Mb)
NF1
REPa
NF1
REPc
LRRC37B
cen
Type-2 NF1 deletion (1.2 Mb)
tel
NF1
REPb
Type-3 NF1 deletion (1.0 Mb)
Figure 1 Schema of the NF1 gene region and relative extents of the different deletion types. The 14 genes located within the NF1 gene
region, and included within the type-1 deletion region, are indicated by horizontal arrows. The direction of each arrow denotes the
transcriptional orientation of the corresponding gene. The relative locations of the low-copy repeats, termed NF1-REPa, NF1-REPb and NF1-REPc
are also indicated by vertical bars. Cen, centromeric; tel, telomeric.
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to be probable germline type-2 deletions.
In the present study, we describe the clinical features
of two patients with non-mosaic type-2 NF1 deletions
and compare their phenotypes to those of patients with
type-1 NF1 deletions. Our aim wast oa s s e s sw h e t h e r
obvious differences exist in relation to the clinical phe-
notypes associated with these two different types of NF1
deletion.
Case presentation
The characterization of the deletion breakpoints of both
patients (2429 and 2358 in [13]) studied here has been
reported previously [13]. Breakpoint analysis indicated
that the deletions were mediated by NAHR between the
SUZ12 gene and SUZ12P. Neither FISH performed on
blood samples nor microsatellite marker analysis using
DNA from buccal swabs yielded any evidence for
somatic mosaicism with normal cells in both patients
[13]. In our first patient (patient 2358 in [13]), FISH was
performed on interphase cells derived from an urine
sample according to the methods described previously
[12]; of 307 nuclei evaluated > 99% exhibited the dele-
tion. We conclude that it is likely that both patients har-
bor non-mosaic (germline) type-2 NF1 deletions.
Patient 1
Our first patient was a prematurely born girl of Cauca-
sian European descent, with a patent foramen ovale
with a minor left-to-right cardiac shunt and pulmonary
valve stenosis (PVS) at birth. However, the PVS dimin-
ished over time. During her pre-school years, she exhib-
ited mild motor and cognitive developmental delay. At
the age of five years, delays in speech and the develop-
ment of articulation were diagnosed. Clinical examina-
tion at the age of 12 years and nine months indicated
normal height and weight (160 cm (50th to 75th percen-
tile) and 59 kg (75th to 90th percentile)). However,
macrocephaly was noted with a head circumference of
56.8 cm (97th percentile). Facial dysmorphic features
including hypertelorism, epicanthic folds, a broad nasal
root and low set ears were observed. She had large
hands and feet and hyperflexibility of the joints. More
than six café-au-lait spots were noted as well as axillary
and inguinal freckling, Lisch nodules and 10 subcuta-
neous neurofibromas. She had slight hypertrichosis on
her lower back and a length difference of the legs. Neu-
rological examination indicated generalized muscular
hypotonia, but she showed adequate coordination and
motor function. Whole body MRI revealed a small plexi-
form neurofibroma of the right calf (9.2 mL, Figure 2A,
B) and an internal plexiform neurofibroma above the
right ankle (Figure 2C). Neither large occult tumors, nor
spinal neurofibromas were identified on whole-body
M R Is c a n s( F i g u r e2 A ) .M R Io ft h eb r a i nr e v e a l e dT 2
hyperintensities in the cerebellum, which are thought to
represent foci of neural dysplasia or dysmyelination.
Neuropsychological testing was not performed. Initially,
our patient attended a regular elementary school and
then, at the age of 12 years and nine months, secondary
school. Severe learning disabilities were not reported,
but owing to attention deficit and impairment in speed
of learning, she needed educational support.
Patient 2
Our second patient was a man of Caucasian European
descent who had shown considerable motor and cogni-
tive developmental delay as a child in his pre-school
years. He was clinically examined by us at the age of 18
years. His body measures were within the normal range
(height: 184 cm (50th to 75th percentile), weight: 62 kg
(10th to 25th percentile)). However, macrocephaly was
noted (head circumference: 60 cm (97th percentile)). He
had large hands and feet and hyperflexibility of the
joints. Facial dysmorphic features including saddle nose
and hypertelorism were noted, as well as a broad neck
and a funnel chest (Figure 3A). A difference in length
between his legs was noted but his spine was in an
orthograde position. MRI of his brain revealed complex
corpus callosum aplasia. Neuropsychological examina-
tion revealed significant visual motor and attention defi-
cits. IQ testing indicated a full scale IQ of 84, a verbal
IQ of 86 and a performance IQ of 85. Our patient
attended regular elementary school and obtained a sec-
ondary school certificate.
He had more than six café-au-lait spots and axillary and
inguinal freckling as well as Lisch nodules. Cardiac exami-
nation showed a right ventricular subvalvular neurofi-
broma (17 × 17 mm), which resulted in a first-degree
pulmonary valve insufficiency. More than 1000 subcuta-
neous and 500 cutaneous neurofibromas were noted (Fig-
ure 3B). Volumetric analysis of whole body MRI scans
indicated a high internal total tumor load of 3896 mL.
Large plexiform neurofibromas (PNs) were detected along
the lumbo-sacral plexus and in the abdomen/pelvis. Smal-
ler PNs were detected within the right lower limb, para-
pharyngeal space, along the brachial plexus and spinal
nerves as well as major peripheral nerves (Figure 4A-C).
Our patient’s primary MPNST (WHO grade IV) evolved
from a pre-existing PN located in the lesser pelvis affecting
the lumbar vertebra L5 and leading to osteolysis of his
sacral and ileac bone. Seven months after surgery, our
patient experienced severe abdominal pain and relapse
was evident on MRI and PET-CT scan (standardized
uptake value (SUV) of 11,5, Figure 4D, E). Our patient
underwent surgery and adjuvant chemotherapy (CWS
protocol) but post-operative staging revealed tumor infil-
tration of the intestine up to the left colon flexure and
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and radiation therapy were initiated. Three weeks before
he died, our patient and his relatives opted to terminate
the maintenance therapy.
Discussion
Comparison of the clinical features of our two patients
with non-mosaic type-2 NF1 deletions reported here
with the manifestations of disease in patients with mole-
cularly ascertained type-1 deletions reported by Mautner
et al., [5] indicated a considerable overlap of their clini-
cal phenotypes. Among the most frequent clinical fea-
tures observed in patients with type-1 NF1 deletions
were dysmorphic facial features, macrocephaly, hyper-
flexibility of the joints, large hands and feet, cognitive
impairment/learning disability, and a high tumor load as
pn
pn
B A
pn
C
Figure 2 Whole body MRI of our first patient indicated a superficial plexiform neurofibroma (pn) of the left calf (A, B) and an internal
plexiform neurofibroma above the right ankle (C).
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Figure 3 (A) Funnel chest and cutaneous neurofibromas on the trunk of our second patient, and multiple subcutaneous
neurofibromas on the back of our patient (B).
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Figure 4 Internal tumor load of our second patient. Whole body MRI (A) indicated multiple tumors along the lumbar nerves (ln), the sciatic
nerves (sn) and within the lumbar plexus (lp). Nodular neurofibromas (nd) were also detected. A coronal image of his head (B) indicated
multiple spinal neurofibromas (sp), which were also detected on MRI images of his trunk (C) as well as neurofibromas within the brachial plexus
(bp) and along the intercostal nerves (in). MRI also showed a high tumor density in the lesser pelvis of our patient (D), including a malignant
peripheral nerve sheath tumor (MPNST) as confirmed by positron emission tomography - computed tomography (PET-CT) (E).
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features were also noted in our second patient. He had
an extremely high internal tumor load (Figure 4), indica-
tive of the severe disease manifestations resulting from
the type-2 NF1 deletion. Our patient died of the compli-
cations associated with a secondary, therapy-resistant
MPNST at the age of 18 years. Patients with large NF1
deletions have been reported to have a substantially
higher risk of development of MPNSTs as compared
with NF1 individuals lacking large NF1 deletions.
Whereas the lifetime risk of an MPNST in all patients
with NF1 is 8% to 13%, patients with NF1 deletion have
an estimated lifetime risko fa nM P N S To f1 6 %t o2 6 %
[7]. In the study of Mautner et al. [5], 21% of the
patients with molecularly ascertained type-1 NF1 dele-
tions had an MPNST, thereby confirming the increased
risk with respect to this malignant tumor experienced
by patients with type-1 NF1 deletions. Our study sug-
gests that patients with type-2 NF1 deletions may also
be subject to an increased risk of MPNSTs. Conse-
quently, patients with this type of deletion should also
receive intensive medical care in order to guarantee
early detection of the malignant transformation of
tumors.
The clinical phenotype observed in our first patient
was milder than the phenotype observed in our second
patient. However, our first patient was only 13 years old
at the time of examination and therefore the load of
age-dependent symptoms (such as number of
neurofibromas) cannot yet be fully assessed. Further-
more, NF1 is generally associated with high variability in
terms of its clinical expression. Hence, some degree of
variability in clinical expression is to be expected in
patients with large deletions. Regardless, our first patient
also exhibited several symptoms known to be associated
with type-1 NF1 deletions such as dysmorphic facial fea-
tures, macrocephaly, large hands and feet, hyperflexibil-
ity of the joints, mild motor and cognitive
developmental delay and T2 hyperintensities. Addition-
ally, she had a congenital heart defect (patent foramen
ovale). Congenital heart defects certainly belong to the
NF1 deletion-associated phenotype as they were also
observed in 21% of patients with type-1 NF1 deletion
[5]. Our second patient also had a pulmonary valve
insufficiency (grade I).
The clinical phenotype observed in our two patients
with putative germline type-2 NF1 deletions reported in
this study is broadly similar to those associated with
type-1 NF1 deletions [5,6]. Also in one of our previous
studies, severe clinical phenotypes were observed in two
patients with germline type-2 NF1 deletions [11]. How-
ever, the patients reported in that study could not be
investigated by us in great detail with respect to their
clinical manifestations; therefore, further conclusions
were not possible [11].
The severe clinical phenotype often associated with
large NF1 deletions has been suggested to represent a
contiguous gene syndrome [6]. Accordingly, the clinical
Table 1 Comparison of the prevalence of clinical features observed in patients with type 1 NF1 deletions as reported
by Mautner et al. [5] with the clinical features noted in our two patients with non-mosaic type-2 NF1 deletions
Clinical features of patients with type-1 NF1 deletions (percentage of patients with this feature)
a Presence or absence of this feature in
our patients by breakpoint
Patient 2429 Patient 2358
Facial dysmorphism (90%) ++
Tall stature (46%)
b --
Large hands and feet (46%) + +
Macrocephaly (39%)
c ++
Learning disabilities (48%) + + (mild)
Attention deficits (33%) ++
Scoliosis (43%) -N A
Hyperflexibility of the joints (72%) + +
Plexiform neurofibromas (76%) + (multiple) +
Subcutaneous neurofibromas (76%) + (multiple) +
Cutaneous neurofibromas (86%) + (multiple) -
MPNST (21%) +-
T2 hyperintensities (45%) -+
Muscular hypotonia (45%) NA +
Congenital heart defects (21%) + +
aAccording to the analysis of 29 patients with type-1 NF1 deletion [5].
bTall stature was denoted if height measurements were at or above the 94th percentile.
cMacrocephaly was denoted if the head circumference was at or above the 97th percentile.
-, absent; +, present; MPNST, malignant peripheral nerve sheath tumor; NA, not assessed.
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not only by the deletion of the NF1 gene but also by the
deletion of flanking genes. In contrast to type-1 dele-
tions, the LRRC37B gene of unknown function is not
included within the deletion interval of type-2 deletions
(Figure 1). As yet, it is unclear whether haploinsuffi-
ciency for the LRRC37B gene exerts any influence on
the clinical phenotype associated with large NF1 dele-
tions. In this context, it seems worthwhile to note that
our two patients clinically investigated in this study did
not exhibit severe mental retardation. In the study of
Mautner et al. [5], 38% of patients with molecularly
assigned type-1 NF1 deletions exhibited severe mental
retardation. Further clinical investigations of additional
patients with NF1 with non-mosaic type-2 NF1 deletions
will be necessary in order to assess whether severe men-
tal retardation is a feature that occurs more often in
association with type-1 than type-2 NF1 deletions.
Conclusions
The clinical phenotype of patients with non-mosaic
type-2 NF1 deletions can be severe and includes most of
the features that have been reported in patients with
type-1 NF1 deletions. Our findings support the existence
of a NF1 microdeletion syndrome caused by type-1 as
well as type-2 NF1 deletions. The additional complica-
tions associated with the NF1 microdeletion syndrome
render the intensive clinical and psychological care of
patients who are affected absolutely necessary.
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